top of page
Depositphotos_204189106_L_edited.png
펨토바이오메드 0504.jpg

Cell Therapy Manufacturing On-Site within 1 - Day.  

Cell Engineering Leader,

Femtobiomed

capa_2x_edited.png

We aim to provide effective therapeutics to patients.

Team leaders of Femtobiomed perform CellShot system R&D, commercialization, operation, and business development and we strive to collaborate with leading therapeutic companies to provide effective cell therapeutics to patients. 

LEADERSHIP TEAM

KakaoTalk_Photo_2023-01-15-16-27-50.jpeg

As the global population ages and various factors, including climate change and the pandemic, impact healthcare, the demand for numerous treatments, including low-molecular compounds, antibody therapies, and gene and cell therapies, has increased. It has increased the cost of the process and manufacturing engineering as organizations invest in technologies that ensure these therapies' secure and cost-effective production.
 
At Femtobiomed, we have been working on research and development for the past ten years, intending to deliver non-viral genetic materials to target cells. In early 2022, we launched our first commercial product, the CellShot device and platform. This technology allows for one-day, on-site treatment through the delivery of non-viral genetic material. It aims to simplify and automate the current manufacturing process for cell therapies. CellShot has the potential to enable small-scale, customized manufacturing to meet the growing demand for cell and gene therapies and minimize the vein-to-vein time.
 
In addition to our focus on developing and improving technology for the pharmaceutical market, we are also committed to sharing our knowledge and experience with institutions and organizations to advance the field of cell therapy. Our team is fully dedicated to meeting the technological needs of the pharmaceutical industry and improving treatment options for patients in need. Our dedication will ultimately reflect in the suitable and acceptable treatment options we provide.

 Juhyun Choi, CEO

  • LinkedIn

    His major is in Stem Cell and Immunology, enhancing Femtobiomed potential in cell therapeutics.

    QUAD / Co-founder of Bridge Bio / Prof. at CHA Medical School

    SANOFI / LG / Korea Univ. Ph.D.

    founder.jpg

    My background is in fusion of micro/nano-engineering with cell mechanics , and I have been striving to innovate nonviral cell engineering since I founded FEMTOBIOMED. In 2022, we launched the CellShot system, which allows transfection to cells in any culture media, eliminating the need for cell washing to exchange the EP buffer, significantly simplifying the overall transfection process, and making it easy to automate. The cost-effective yet superior performance of the CellShot platform contributes to the innovation of cell and gene therapeutics industry. 

    Sanghyun Lee, Founder & Co-CEO

    • LinkedIn

    - Ph.D. at U of M (ME, Mircofluidics, Prof. Edgar Mayhoffer)

    - PostDoc. at U of M (BME, Quantitative Cell Mechanics, Prof. Alan J. Hunt)

    - Research Prof. at POSTECH (ME, Nanoscale intracellular injection)

    cto.jpg

    Junkwon Park
    CTO

    He creates the brain of CellShot system using extensive expertise in software, firmware, electronics and database.

     

    - Ph.D. at POSTECH (ME)

    • LinkedIn
    cfo.jpg

    Whasub Choi
    CFO

    He has over 20 years of experience in finance and business management at corporations such as Samsung and Taekwang. He leads the investor relations and management at Femtobiomed.

    - Samsung, Korea

    - MBA at SKKU

    • LinkedIn
    펨토바이오메드 0266.jpg

    Jinook Lee
    Head of BD

    He identifies and secures strategic partnerships to drive the growth of the company with a background in mechanical engineering.

    - Accenture UK

    - MEng at Imperial College London

    • LinkedIn

    HISTORY

    2021-2022

    CellShot Commercialization

    2022

    • Series C Fundraising (Ryukyung PSG, 4M USD)

    • CellShot® CE Marking

    • NET Certification (Real Time Direct Transfection technology for mRNA delivery into cells)

    • MOU signed with Seoul St.Mary’s Hospital for Joint Development of cell therapeutics using CellShot

    • Development of automated process device - CellShot® 

    • Assignment of  the Korean government’s research project (4M USD)

    2021

    • CellShot® mRNA CAR-NK Manufacturing

    • CellShot® mRNA eGFP-NK Manufacturing

    • CellShot® Patent registered in Japan

    • Series B Bridge Fundraising (QUAD / Hana Finance Investment, 6M)

    2016-2020

    CellShot Platform
    Development

    2020

    • CellShot patent registered in Europe

    2019

    • IPO on KONEX

    • Series B Fundraising (Widwininvest, Korean Investment Partners)

    2018

    • CellShot Patent registered in the US

    • CellShot Master System Device Release

    2017

    • Corporate name and headquarters changed to FEMTOBIOMED and Pangyo

    2016

    • Series A Fundraising – Korean Investment Partners and Hanhwa Investment (3M USD)

    • Company Valuation of 22M USD

    2011-2015

    FEMTOFAB and Research Foundation

    2015

    • Company Valuation of 10M USD 

    2014

    • Development of CellShot 3D protein injection chip

    • Patent application for CellShot cell chip

    2013

    • Establishment of corporate in-house research institute

    • CE Marking for SmartDrop® 

    2012

    • Release of SmartDrop® and Ft-nano station

    • Venture Company Registration

    2011

    • Establishment of FEMTOFAB and 300K Angel Investment 

    Let’s Work Together

    17 Pangyoro-228-beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do,

    Republic of Korea.

    Tel: 82.031.622.8501

    Thanks for submitting!
    bottom of page